Werewolf Therapeutics, Inc. (HOWL) News
Filter HOWL News Items
HOWL News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Latest HOWL News From Around the Web
Below are the latest news stories about WEREWOLF THERAPEUTICS INC that investors may wish to consider to help them evaluate HOWL as an investment opportunity.
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare ConferenceWATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werew |
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals - - Additional preclinical data demonstrate INDUKINETM molecules’ anti-tumor potency with distinct immune activation profiles across four cytokines - WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical compan |
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update– Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting – – Monotherapy and combination expansion arms open and enrolling in ongoing Phase 1/1b clinical trial of WTX-124; initial efficacy data from monotherapy expansion arms anticipated in the first half of 2025 – – Introduced WTX-921, a promising new development candidate and first-of-its kind IL-10 INDUKINE™ molecule for the treatment of inf |
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory DiseasesWATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced the addition of WTX-921, a novel IL-10 INDUKINE development candidate for Inflammatory Bowel Disease (IBD) and potentially other inflamm |
Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ StocksWe’re well into Q4, and investors are positioning their portfolios for the coming year. As always, the key is identifying stocks poised to deliver solid returns, and Bank of America has highlighted strong choices for those seeking high-growth opportunities. BofA’s analysts aren’t limiting their focus to just one part of the market; they are looking across sectors at a diverse group of stocks – and they are looking ‘under the hood’ to find shares that are ready to jump. With that in mind, we turn |
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingWATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas. Det |
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceWATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside |
Werewolf Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsWerewolf Therapeutics ( NASDAQ:HOWL ) Second Quarter 2024 Results Key Financial Results Net loss: US$17.2m (loss... |
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue EstimatesWerewolf Therapeutics (HOWL) delivered earnings and revenue surprises of -13.16% and 42.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? |
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting – – Encouraging signs of clinical activity at tolerable doses disclosed from ongoing Phase 1 clinical trial of WTX-330 – – Updated data on WTX-124 in combination with pembrolizumab and opening of expansion arms anticipated in the second half of 2024 – – Update on WTX-330 dose escalation and expansion data anticipated at a medical meeting in the fourth quarter |